Clinical Trials on Intraocular Melanoma in New Zealand

Total 824 results

Roswell Park Cancer Institute
National Cancer Institute (NCI); National Comprehensive Cancer Network

Terminated

Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...

United States
Ichor Medical Systems Incorporated
Memorial Sloan Kettering Cancer Center

Completed

Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation

Intraocular Melanoma | Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
Delcath Systems Inc.
National Cancer Institute (NCI)

Completed

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Metastatic Cancer | Intraocular Melanoma | Melanoma (Skin)

United States
Antisoma Research

Completed

Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma

Metastatic Renal Cell Carcinoma | Metastatic Malignant Melanoma

United Kingdom, New Zealand
Hoffmann-La Roche

Completed

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Malignant Melanoma, Neoplasms

Spain, New Zealand, Hungary, Serbia, Germany, Portugal, Netherlands, Greece, Australia
Piramal Enterprises Limited

Completed

Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression (ENVER)

Melanoma

Australia, India, New Zealand
National Cancer Institute (NCI)

Completed

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Iris Melanoma | Stage IV Uveal Melanoma | Medium/Large Size Posterior Uveal Melanoma | Recurrent Uveal Melanoma | Ocular Melanoma With Extraocular Extension | Small Size Posterior Uveal Melanoma

United States, Canada
Ludwig Institute for Cancer Research
Institute of Cancer Research, United Kingdom

Completed

Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma

Melanoma

United Kingdom, Australia, New Zealand
Morphotek

Terminated

A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma

Melanoma | Metastatic Melanoma | Advanced Melanoma | Malignant Metastatic Melanoma

United States
Trans Tasman Radiation Oncology Group
University Medical Center Groningen; Australian and New Zealand Intensive Care...

Completed

Immediate Radiotherapy or Observation After Surgery for Melanoma Involving Lymph Nodes

Lymph Node Disease | Malignant Melanoma

Australia, New Zealand, Netherlands, Brazil
National Cancer Institute (NCI)

Terminated

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
National Cancer Institute (NCI)

Withdrawn

RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery

Stage IV Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
CINJRegulatory
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Terminated

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
National Cancer Institute (NCI)

Terminated

Tanespimycin in Treating Patients With Stage III-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Completed

Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

Melanoma (Skin)

United States
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Terminated

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

Melanoma (Skin)

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); University of Virginia

Completed

Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma

Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin Melanoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Stage IV Melanoma | Stage III Melanoma

United States
Rajiv Gandhi Cancer Institute & Research Center...

Completed

Quantitative Rise in Intraocular Pressure in Steep Trendelenburg Position

Intraocular Pressure

India
Syneos Health
Oncolys BioPharma Inc

Unknown

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

Melanoma Stage Iv | Melanoma Stage III

United States
Memorial Sloan Kettering Cancer Center

Completed

A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery

Cutaneous Melanoma

United States
National Cancer Institute (NCI)

Completed

BMS-247550 in Treating Patients With Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Bausch & Lomb Incorporated

Completed

Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers (KRONUS)

Intraocular Pressure

United States
Roswell Park Cancer Institute

Completed

Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy

Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IB Skin Melanoma

United States
National Cancer Institute (NCI)

Completed

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
Ludwig Institute for Cancer Research
Cancer Research Institute (CRI)

Completed

NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)

Malignant Melanoma

United States
Parker Institute for Cancer Immunotherapy
Seres Therapeutics, Inc.

Completed

Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW)

Metastatic Melanoma

United States
Bristol-Myers Squibb

Completed

Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma (CheckMate 069)

Metastatic Melanoma | Unresectable Melanoma

United States, France
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Acral Lentiginous Malignant Melanoma

United States
NYU Langone Health

Terminated

Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma

Metastatic Melanoma

United States
NYU Langone Health
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma

Melanoma (Skin)

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Completed

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Melanoma (Skin)

United States
Celgene
NYU Langone Health; Syneos Health; Celerion; ApoCell, Inc.

Completed

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

Malignant Melanoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Withdrawn

Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Terminated

CP-461 in the Treatment of Patients With Advanced Melanoma

Malignant Melanoma

United States
Memorial Sloan Kettering Cancer Center
Yale University; University of New Mexico

Completed

Differential Risks for Melanoma: p16 and DNA Repair

Melanoma | Skin Melanoma

United States
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center

Completed

Study of gp75 Vaccine in Patients With Stage III and IV Melanoma

Malignant Melanoma

United States
Dartmouth-Hitchcock Medical Center

Terminated

Metronomic Therapy in Patients With Metastatic Melanoma

Metastatic Melanoma

United States
Yale University
Novartis

Terminated

A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma

Metastatic Melanoma

United States
Bristol-Myers Squibb
Medarex; Ono Pharma USA Inc

Completed

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Malignant Melanoma

United States
Columbia University
Merck Sharp & Dohme LLC

Terminated

MRI and PET to Assess Pembrolizumab Response (MPAK)

Malignant Melanoma, Metastatic

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma

United States
Melanoma Institute Australia
Merck Sharp & Dohme LLC

Not yet recruiting

Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (Neo PeLeMM)

Mucosal Melanoma

Australia
Memorial Sloan Kettering Cancer Center
Pfizer

Recruiting

Axitinib and Nivolumab for the Treatment of Mucosal Melanoma

Mucosal Melanoma

United States
Yale University

Terminated

A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes

Metastatic Melanoma

United States

Clinical Trials on Intraocular Melanoma in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations